TOKYO (Reuters) – Japan’s Fujifilm Holdings Corp said on Friday it was halting enrolment in a Phase III trial of its antiviral pill Avigan for the treatment of COVID-19.
The emergence of Omicron made it difficult to determine the drug’s effectiveness in preventing progression to severe symptoms, the company said in a statement. Clinical data of the patients already enrolled in the trial will continue to be analysed, it said.
(Reporting by Rocky Swift; Editing by David Dolan)
